Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2024-09-16 00:00:00 ET · period of report 2024-09-12 · accession 0000950170-24-106910 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-16 | 2024-09-12 | AMLX | FRATES JAMES M | CFO | P - Purchase | $2.53 | +40.0K | 233.5K | +21% | +$101.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-12 | P | A | 40,000 | $2.53 | 233,464 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.4849 to $2.63. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. |